Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is there pseudoprogression in secondary glioblastomas?

International journal of radiation oncology, biology, physics - 1 Dec 2013

Juratli Tareq A, Engellandt Kay, Lautenschlaeger Tim, Geiger Kathrin D, von Kummer Rüdiger, Cerhova Jana, Chakravarti Arnab, Krex Dietmar, Schackert Gabriele

Abstract excerpt

PURPOSE: Pseudoprogression (PP) during adjuvant treatment of glioblastoma (GBM) is frequent and is a clinically and radiologically challenging problem. While there are several reports of the frequency of PP in GBM cohorts including mainly patients with primary GBM, there are few data on the incidence of PP in patients with secondary glioblastomas (sGBM). Therefore, the goal of this study was to evaluate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to DNA Modification Methylases

Share to DNA Repair Enzymes

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 24267971
DOI: 10.1016/j.ijrobp.2013.09.036
PMCID: PMC4349215

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is there pseudoprogression in secondary glioblastomas?PMID 24267971Read ↗

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.Semantic proximity Read ↗

MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma PatientsSemantic proximity Read ↗

Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.Semantic proximity Read ↗

Pseudoprogression in high-grade glioma.Semantic proximity Read ↗

IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.Semantic proximity Read ↗

Treatment of Glioblastoma.Semantic proximity Read ↗

The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis.Semantic proximity Read ↗

IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.Semantic proximity Read ↗

The extent of resection and adjuvant treatment are beneficial to the outcome of secondary glioblastomaSemantic proximity Read ↗

Quantitative analysis of MGMT promoter methylation status changes by pyrosequencing in recurrent glioblastomaSemantic proximity Read ↗

Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics studySemantic proximity Read ↗

Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.